



SCIENTIFIC COMPANY KOLIBRI LLC

GENERAL DATA PROTECTION REGULATORY (GDPR)

COMPLIANCE WHITE PAPER

Introduction

As a developer, manufacturer, and supplier of noninvasive medical devices, SCIENTIFIC COMPANY KOLIBRI LLC is dedicated to delivering high-quality, richly featured medical products making healthcare more accessible and affordable worldwide. Since founded in 2021, SCIENTIFIC COMPANY KOLIBRI LLC has been striving to provide medical devices and industry solutions and practice corporate value into every aspect of the company. To better serve clients, SCIENTIFIC COMPANY KOLIBRI LLC follows the most stringent international and CE manufacturing and quality control standards in each of its state-of-the-art manufacturing facilities, ensuring efficiency and traceability throughout the entire process.

This White Paper aims to provide our clients and stakeholders information to understand the SCIENTIFIC COMPANY KOLIBRI LLC privacy policy better. Specifically, this White Paper describes how SCIENTIFIC COMPANY KOLIBRI LLC implements its privacy policy to collect, store, transfer and delete data in the process of product design, manufacture, sales and use.

With the effective date of General Data Protection Regulation (GDPR) of European Union, SCIENTIFIC COMPANY KOLIBRI LLC has been taking practical actions to comply with GDPR compliance frameworks. SCIENTIFIC COMPANY KOLIBRI LLC is a leading practitioner at the forefront of industry compliance practices all along. In this White Paper, it will help you to understand:

- SCIENTIFIC COMPANY KOLIBRI LLC overall privacy protection policy, including guiding principles adopted by SCIENTIFIC COMPANY KOLIBRI LLC Headquarters and its subsidiaries;
- SCIENTIFIC COMPANY KOLIBRI LLC GDPR compliance programme illustrating the corporate governance and internal controls with regards to the considerations of privacy protection;
- The mechanism of SCIENTIFIC COMPANY KOLIBRI LLC products, including NID (non invasive diagnostic), ESWT (shock-wave therapy), LIT (Low Intensity VHF-UHF therapy) on how to collect, store, transfer and delete data.

Disclaimer:

This White Paper is provided solely for informational purposes and aimed to help existing and prospective business partners understand how SCIENTIFIC COMPANY KOLIBRI LLC may facilitate your compliance with the GDPR. It shall not be construed or used as legal advice about the GDPR, its implementing rules or regulatory guidelines. The White Paper summarises



KOLIBRI

SCIENTIFIC COMPANY KOLIBRI LLC GDPR compliance measures and status as of the release date of this document and is subject to future changes without prior notice. As each business partner may have substantially different demands and may be operating under different personal data protection regimes, SCIENTIFIC COMPANY KOLIBRI LLC strongly encourages you to obtain properly customised legal advice on personal data protection in general, and the GDPR compliance in particular. This White Paper does not constitute or create any warranties, responsibilities, representations, contractual commitments, conditions, endorsement or assurances from SCIENTIFIC COMPANY KOLIBRI LLC.

Our Vision

Better healthcare for all.

Our Mission

Advanced medical technologies to make healthcare more accessible.

Our Commitment

SCIENTIFIC COMPANY KOLIBRI LLC is strongly committed to protecting the privacy of personal data that they maintain about our clients, employees and other individuals. As part of this commitment to confidentiality, SCIENTIFIC COMPANY KOLIBRI LLC regularly reviews its data protection practices to comply with applicable laws, industry standards and best practices. SCIENTIFIC COMPANY KOLIBRI LLC is now in the process of implementing the requirements of GDPR, building on existing confidentiality and security processes and standards. The new GDPR compliance programme is extensive and covers multiple functional areas and aspects of our business, all in pursuit of accountability and transparency in how SCIENTIFIC COMPANY KOLIBRI LLC collects, process, protects and disposes of personal data. SCIENTIFIC COMPANY KOLIBRI LLC continuous improvement in this area is a long-lasting mission.

GDPR briefing

GDPR Overview:

A Regulatory Change

As is becoming effective on May 25, 2018, General Data Protection Regulation (GDPR) deal with personal data and intend to give individuals more control over their data. The new GDPR impose a regulatory framework in Europe and the broader world for the processing of personal data relating to an individual in the EU. Compared to the prior regulation.

GDPR shifts the focus from organisational responsibilities to the rights of individuals by strengthening their ability to know where it is, how it is being used, making sure it is correct, to have it deleted or transferred, and to object to it being used.

This regulation shift changes the way organisations or companies to collect and process data, especially some categories of personal data (health, ethnicity, religion, biometrics, sexual orientation, etc.) having even more demanding conditions. Accordingly, there is a new requirement for organisations or companies to document their processing activities of how they are protecting personal data and using lawfully, fairly and transparently.

Is SCIENTIFIC COMPANY KOLIBRI LLC well prepared for GDPR?



KOLIBRI

SCIENTIFIC COMPANY KOLIBRI LLC is working closely with its staff, clients and third parties about the GDPR compliance programme between Headquarters and Europe. According to GDPR requirements, SCIENTIFIC COMPANY KOLIBRI LLC implements reasonable and appropriate organisational and technical measures to ensure that the nature, scope, context and purpose of our products are under a regulatory framework.

SCIENTIFIC COMPANY KOLIBRI LLC practices «Privacy by Design» and our products have been designed with the considerations relevant to GDPR requirements from the beginning of the project and throughout the entire lifecycle.

How we protect our clients information

SCIENTIFIC COMPANY KOLIBRI LLC General Data Protection Regulation (GDPR) Programme

Given SCIENTIFIC COMPANY KOLIBRI LLC global footprint and expansive business model, our company sit at the convergence of market demands and regulatory forces related to data, especially the GDPR.

SCIENTIFIC COMPANY KOLIBRI LLC intends to build the programme on the existing Information Protection Standard and is designed to achieve a level of enhanced baseline uniformity across the globe, informed chiefly by the prevailing and dominant legal requirements, emerging client demands, and the need to facilitate the realisation of SCIENTIFIC COMPANY KOLIBRI LLC commercial targets.


To better meet GDPR compliance requirements and protect customer's privacy, SCIENTIFIC COMPANY KOLIBRI LLC has launched a GDPR compliance programme positively and proactively. In accordance to GDPR compliance core areas, SCIENTIFIC COMPANY KOLIBRI LLC will demonstrate the security of the data processing and compliance with the GDPR continually, by implementing and regularly reviewing robust technical and organisational measures, as well as compliance policies in this White Paper.

SCIENTIFIC COMPANY KOLIBRI LLC GDPR Compliance Programme Organisation Chart

In accordance with the requirement of GDPR, SCIENTIFIC COMPANY KOLIBRI LLC improves and develops the corporate governance structure. The compliance governance structure is a modernised, accountability-based framework that facilitates internal control and response to data breach issues. The organisational structure should be clear and reliable so that every relevant department is involve in data protection activities. From top to bottom, the GDPR compliance organisational structure is as shown below.



KOLIBRI



The GDPR compliance organisational structure has been divided into three core responsibility areas and is as follows:

- The GDPR Compliance Senior Management provides compliance strategic vision and plan, as well as performs tactical and strategic management of the GDPR Programme;
- The Data Protection Officer (DPO) is in charge of daily compliance operation and coordinates the functioning of internal departments;
- The internal departments within the company perform the day-to-day GDPR operational activities.

The Data Protection Officer (DPO) is the core role of the GDPR compliance programme. This role is responsible for the day-to-day operations of the compliance activities. The DPO is involved, properly and in a timely manner, in all issues which relate to the protection of personal data. The responsibilities of DPO are including:

- Managing compliance violations;
- Working with relevant business units to enhance their awareness and propose corrective measures;
- Following up with the updates from regulators and notifying the appropriate parties;
- Determining the adequacy of the inclusivity of data protection clauses in contracts;
- Reviewing and commenting on the data protection clauses from the client.

SCIENTIFIC COMPANY KOLIBRI LLC Corporate Practices in Privacy Protection

1. Privacy by Design

Privacy by Design is such an approach applied to system/product engineering that promotes privacy and data protection compliance from the beginning of the project and throughout the



KOLIBRI

entire lifecycle. Taking Privacy by Design approach is an essential tool in minimising privacy risks and building trust with our clients. Designing projects, processes, products or systems with privacy in mind at the outset can lead to the benefits that include:

- Potential problems identified at an early stage, when addressing them will often be simpler and less costly;
- Increased awareness of privacy and data protection across an organisation;
- Organisations are more likely to meet their legal obligations and less likely to breach the laws;
- Actions are less likely to be privacy intrusive and harm individuals. From a more essential and specific perspective, this approach will help organisations comply with their obligations under legislation. For example, the General Data Protection Regulation (GDPR) from the European Union clearly defines the requirements and obligations of the company and organisation to take positive and valid measures of data protection. These measures can be classified into two types, organisational and technical. Organisations shall modify and optimise internal control processes based on GDPR. This encourages a cultural change to consider privacy and security controls and safeguards throughout the data lifecycle process. Specifically, these controls contain the data minimisation, access controls, retention, accessibility and other factors in the design phase. Since its foundation, SCIENTIFIC COMPANY KOLIBRI LLC has attached great importance to the privacy protection of its clients all along. A completely well-designed and stringent internal control system has established and been implementing for more than two decades.

SCIENTIFIC COMPANY KOLIBRI LLC takes practical actions in advance to comply with the regulation. Specifically, SCIENTIFIC COMPANY KOLIBRI LLC develops an efficient work plan to assess and improve current processes, as shown below.

- Privacy Impact Assessment (PIA):

Assess current-state privacy controls throughout the product development lifecycle, and identify compliance gaps and risks in data privacy;

- Privacy-by-Design (PbD)

Implementation Roadmap: Assist in the Design and implementation of PbD framework at the enterprise level, with enhancements to technology, policies, procedures, and operations;

- PbD Recommendations Report:

Continuously enhance and update privacy controls in response to new risks and regulations.

SCIENTIFIC COMPANY KOLIBRI LLC hopes to protect client's privacy through practical and useful actions. This will benefit clients:

- Using the information in a way that people would reasonably expect. This may involve undertaking research to understand people's expectations about how their data will be used;
- Thinking about the impact of your processing. Will it have unjustified adverse effects on them? and;
- Being transparent and ensuring that people know how their information will be used. This means providing privacy notices or making them available, using the most appropriate mechanisms.

2. Data Lifecycle Management

Data Lifecycle Management (DLM) is a policy-based approach to managing the flow of an information system's data throughout its life cycle: from creation and initial storage to the time when it becomes obsolete and is deleted.

DLM includes every phase of a "record" from its beginning to its end. To some extent, DLM means a corporate management control of all informational assets. During its existence,



KOLIBRI

information can become a record by being identified as documenting a business transaction or as satisfying a business need. In this sense, DLM has been part of the overall approach of enterprise content management.

DLM, as a new management method, has the following on offer to promote business transformation and revolution:

- Fully incorporate the technical aspects, performance and cost along with the schedule requirements into a holistic work pack with complete traceability to client demands all through the lifecycle;
- Plan as well as implement the plan with comprehensive configuration management of designs and documents including the program management artefacts;
- Seamlessly and securely collaborate and contribute to the existing knowledge base and share best practices across the total value chain;
- Have a unique master single source of truth of consolidated data with which are used to define most complex medical devices and platforms of SCIENTIFIC COMPANY KOLIBRI LLC and integrate a virtual global network of product developers, designers, production specialists, manufacturing engineers and service/support teams.

Moreover, due to the enormous value of personal data and severe consequence of data leakage, major countries and regions worldwide have accelerated the legislative process to protect personal data and privacy. General Data Protection Regulation (GDPR) from the European Union is a representative example.

Country/Region	Law/Regulation	Issue Date
United States	Health Insurance Portability and Accountability Act of 1996 (HIPAA)	1996
European Union	General Data Protection Regulation (GDPR)	2016
China	People's Republic of China Network Security Law	2017
Hong Kong SAR of PRC	Personal Data (Privacy) Ordinance	1996
Australia	Privacy Act 1988	1988
New Zealand	Privacy Act 1993	1993
Japan	Personal Information Protection Law	2005
Republic of Korea	Personal Information Protection Law	2011
Republic of Singapore	Personal Information Protection Law	2013

What is more important is an understanding of what the GDPR is really seeking to achieve, what the real risk issues are; how to prioritise compliance activity; and how to build appropriate structures for compliance. The GDPR is seeking to (1) put people back in control of their personal data and (2) improve the protections for personal data at the entity's side. Under these circumstances, SCIENTIFIC COMPANY KOLIBRI LLC adjusts corporate governance and refines internal control policies in time to meet GDPR requirements.

Table 1.

<p>1. Data collection <i>The processes by which organisations collect data by various means and methods based on the identification of datasets required to achieve the</i></p>		<p>5. Data transfer <i>The act of transferring data across systems internally within departments or intra-group, or the transfer of data to external third</i></p>
---	--	--



<p><i>defined purposes of the organization.</i></p>	<p>Data interactions</p>	<p><i>parties; some transfer could be cross-jurisdictional.</i></p>
<p>2. Data quality & pre-processing <i>The processes by which organisations transform raw data into an understandable format. Pre-processing involves steps such as cleansing incomplete, noisy or inconsistent data, integrating datasets together and correcting any discrepancies that arise therein, and transforming data by normalizing, aggregating and generalizing.</i></p>		<p>6. Data usage <i>The processing activities conducted to achieve the business purpose.</i></p>
<p>3. Data storage <i>The processes by which an organization stores data for access and use by various stakeholders.</i></p>		<p>7. Data sharing <i>The disclosure of data from an organization(s) to a third party organization(s), or the sharing of data between different parts of an organization. This could be systematic, routine data sharing where the same data sets are shared between the same organisations for an established purpose; or exceptional, one-off decisions to share data for various purpose.</i></p>
<p>4. Data access <i>Access of the data by stakeholder (both internal and external) who require the data to fulfil the processing activity. Access permissions may vary between read only, copy, write/edit, and delete.</i></p>		<p>8. Data retention or deletion <i>The archiving of data or secure disposal of data once the process purpose has been achieved, legislative retention requirements met and the defined and agreed retention timescales have expired.</i></p>

According to GDPR, SCIENTIFIC COMPANY KOLIBRI LLC divides data lifecycle into several phases and develops critical controls at each stage. SCIENTIFIC COMPANY KOLIBRI LLC designs each essential control by GDPR requirements and the company’s business practice. Here take data collection, data storage, data transfer phases as typical examples as shown in the table below:

Table 2.

Data Lifecycle Phase	SCIENTIFIC COMPANY KOLIBRI LLC Efforts	GDPR Core Requirements
1. Data Collection	SCIENTIFIC COMPANY KOLIBRI LLC will clarify responsibilities and obligations about personal information protection with the cooperative medical institutions in signed contract;	Consent
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure that clinical trial participants or product users have signed informed consent form with medical institutions;	
	SCIENTIFIC COMPANY KOLIBRI LLC will follow the process control requirements of Privacy by Design in the implementation of the software development and testing phase;	Privacy by Design
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure only really necessary personal identifiable information (PII) and protected health information (PHI) collected.	Data Concerning Health Scope
2. Data Storage	SCIENTIFIC COMPANY KOLIBRI LLC will ensure collected data is stored securely. Both logical and physical security control measures are deployed under implementation;	Data Protection
	SCIENTIFIC COMPANY KOLIBRI LLC will take appropriate measures considering (1) the state of the art (2) the cost of implementation (3) the nature, scope, context and purposes of the processing and (4) the risk posed to data subjects;	Data Protection by Design
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure that, by default, collected data isn't made available to an indefinite number of people without some action by the data subject;	Data Protection by Default
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure collected data will be stored under the premise (1) as required by professional standards or policies (2) as required or permitted by law.	Lawful Retention of Personal Data



3. Data Transfer	SCIENTIFIC COMPANY KOLIBRI LLC will ensure that the contract signed between the medical institutions and test subject includes the clause fully informs the test subject of cross-border transfer;	Consent
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure that there is a liability clause of cross-border transfer between medical institutions (data senders) and SCIENTIFIC COMPANY KOLIBRI LLC headquarters (data receivers);	
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure the cross-border transfer of data security and compliance;	Data Protection
	SCIENTIFIC COMPANY KOLIBRI LLC will ensure only the necessary data is transferred to comply with the regulation.	Privacy by Design

3. Privacy Notice

SCIENTIFIC COMPANY KOLIBRI LLC respects and values user privacy. Accordingly, SCIENTIFIC COMPANY KOLIBRI LLC has drafted a detailed privacy notice to help the user understand our privacy policy and responsibility. SCIENTIFIC COMPANY KOLIBRI LLC understands that users trust us with their data. Hence, SCIENTIFIC COMPANY KOLIBRI LLC takes this trust seriously and is committed to respecting each user’s privacy and protecting the personal data we handle. There are two approaches to help users to know the privacy policy of SCIENTIFIC COMPANY KOLIBRI LLC better. The first one is the Privacy Notice link at the bottom of our result of diagnostics.

The other one is in a particular form that is sent to our users. They can easily find the Privacy Notice link in the email and get more information from the external page. The SCIENTIFIC COMPANY KOLIBRI LLC Privacy Notice informs our users about the following topics regarding their privacy:

- What personal data will SCIENTIFIC COMPANY KOLIBRI LLC collect and process?
- How SCIENTIFIC COMPANY KOLIBRI LLC use your (personal) data?
- How does SCIENTIFIC COMPANY KOLIBRI LLC protect your (personal) data?
- With whom SCIENTIFIC COMPANY KOLIBRI LLC shares your (personal) data?
- How SCIENTIFIC COMPANY KOLIBRI LLC respects your privacy in marketing activities?
- How to request access to your (personal) data?
- How to contact SCIENTIFIC COMPANY KOLIBRI LLC?

4. Decontamination Process

The SCIENTIFIC COMPANY KOLIBRI LLC company has developed a method for deactivating personal data that is used in cloud software.



a) For USPIH cloud software:

The use of personal data is completely excluded. The USPIH software uses for processing on a cloud mathematical server: temperature values, gender, patient weight, patient age, pulse, atmospheric pressure and respiratory rate. This data does not apply to personal data.

b) For the software of the Personal screening non-invasive diagnostic system of KOLIBRI:

For cloud and local software, a mechanism has been implemented to delete personal data stored in the user's account (last name, first name, date of birth, e-mail) at the request of the client. To delete personal data together with your personal electronic account, you must follow the deletion procedure (pressing a button) and confirm the deletion of personal data and your personal electronic account in your e-mail. You must remember that such data as weight, height, gender, race, age and electronic signals sent by you to the cloud mathematical server for processing will remain in our database, but they will be impersonal and not related to personal data. After the destruction of your (personal) data and personal account, the restoration of the results of your non-invasive diagnostics becomes impossible.

How our products are designed to meet the requirements of GDPR.

Company comprehensive product portfolio, built on a foundation of a thorough understanding of our customer's needs, enables us to offer the right solution for several different care environments, including pre-hospital diagnostic and hospital diagnostic. Company extensive global R&D network utilises cutting-edge technology and translates it into customised healthcare solutions. KOLIBRI integrated innovation platform combined with a commitment to product and service quality has positioned SCIENTIFIC COMPANY KOLIBRI LLC as one of the leading clinical solution providers, making better healthcare more accessible to humanity.

While SCIENTIFIC COMPANY KOLIBRI LLC products insist on the pursuit of quality and technology, we are strongly committed to protecting user personal information as well. As part of our efforts to enhance personal data protection practices and comply with evolving regulations around data privacy, we have robust and practical measures at the product level to provide our users and clients in compliance with laws and regulations, e.g. GDPR.

With the General Data Protection Regulation (GDPR), SCIENTIFIC COMPANY KOLIBRI LLC has taken reasonable and necessary measures to safeguard all the products that comply.

Biopromin's products offer many built-in functionalities that help users lower the possibility of data breach incidents and respond to a data subject's requests.

The following descriptions are specifically illustrating our products' ability to ensure ongoing confidentiality, integrity, availability under the framework of GDPR. The tables below are an overview to show how our products are meeting the principles and data subject rights of GDPR.



Table 3.

GDPR principles relating to processing of personal data	Products		
	NID (AMP, ANESA, DAD-ANI with software USPIH, KOLIBRI with software KOLIBRI)	ESWT (StarDevice with software StarDevice)	LIT (BIOL)
Lawfulness, Fairness and Transparency	N/A	N/A	N/A
Purpose Limitation	*	*	*
Data Minimisation	*	*	*
Accuracy	N/A	N/A	N/A
Storage Limitation	*	*	*
Integrity and Confidentiality	*	*	*
Accountability	*	*	*

Remarks: According to GDPR, the principle with N/A is not applicable to company product functionality because it is solely related to a controller's actions in nature. SCIENTIFIC COMPANY KOLIBRI LLC respects and is fully aware of the principle, however, the compliance to such principle is irrelevant to company product functionality.

Table 4.

GDPR rights of the data subject	Products		
	NID (AMP, ANESA, DAD-ANI with software USPIH, KOLIBRI with software KOLIBRI)	ESWT (StarDevice with software StarDevice)	LIT (BIOL)
Right of access by the data subject	*	*	*
Right to rectification	*	*	*
Right to erasure (Right to be forgotten)	*	*	*
Right to restriction of processing	*	*	*
Notification obligation regarding rectification or erasure of personal data or restriction of processing	*	*	*
Right to data portability	*	*	*
Right to object	N/A	N/A	N/A



KOLIBRI

Automated individual decision-making, including profiling	*	*	*
---	---	---	---

Remarks: According to GDPR, the data subject's right with N/A is not applicable to company product functionality because it is solely related to a controller's actions in nature. SCIENTIFIC COMPANY KOLIBRI LLC respects and is fully aware of these rights, however, the compliance to such rights is irrelevant to company product functionality.

GDPR Principles Relating to Processing of Personal Data.

General Data Protection Regulation (GDPR) into on May 25, 2018. The new legislation leads to the most significant impact on both organisations and European citizens. In GDPR, it outlines seven principles about personal process data. The GDPR principles form the fundamental conditions that organisations must follow when collecting, processing and managing the personal data for all European citizens.

1. Purpose Limitation

GDPR Article 5 (b): collected for specified, explicit and legitimate purposes and not further processed in a manner that is incompatible with those purposes; further processing for archiving purposes in the public interest, scientific or historical research purposes or statistical purposes shall, in accordance with Article 89(1), not be considered to be incompatible with the initial purposes.

The purpose of Company products is clear and explicit. Our products are used for noninvasive screening diagnosis and treatment, safer patient care and other medical service purposes. The products are following Company internal data protection policy and external legitimate law requirements. Company products will never use the patient's data for any other purposes beyond medical service.

All the medical devices and software functions and detailed operation instructions can be found and checked in the product manual book (IFU).

2. Data Minimisation

GDPR Article 5 (c): adequate, relevant and limited to what is necessary for relation to the purposes for which they are processed.

SCIENTIFIC COMPANY KOLIBRI LLC ensures that personal data is collected for specified, explicit and legitimate purposes and not further processed in a manner that is incompatible with those purposes. SCIENTIFIC COMPANY KOLIBRI LLC will not receive (collect) extra personal data that is irrelevant with product use purpose. For example, Company NID products will collect the following information for medical service:

Personally, Identifiable Information:

1. Name, Surname
2. ID
3. Gender
4. Date of Birth
5. Race
6. E-mail
7. Phone






KOLIBRI

Medical and Health Information:

8. Patient ID
9. Age
10. Weight
11. Pulse
12. Respiratory rate
13. Blood type
14. Rh factor
15. Smoking
16. Drugs
17. Type of the Diabet
18. Test Date
19. Comment/Notes
20. Diagnosis
21. Ordering Date
22. Operator
23. Ordering Department
24. Diagnostic Results
25. Medical education (Specialization, Category, Science degree – only for doctors)

Table 5.

NID (AMP, ANESA, DAD-ANI with software USPIH)	
<div style="border: 1px solid gray; padding: 5px;"><p>New patient [X]</p><p>Name: <input type="text"/></p><p><input type="checkbox"/> Use additional identification(ID): <input type="text"/></p><p>Group: <input type="text"/></p><p>Gender: <input type="text" value="female"/>  </p><p style="text-align: right;"><input type="button" value="Yes"/> <input type="button" value="Cancel"/></p></div>	<div style="border: 1px solid gray; padding: 5px;"><p>New examination [X]</p><p>Name: <input type="text" value="UA Patient1"/></p><p>Age: <input type="text"/> (Permissible range: 18 - 100)</p><p>Weight: <input type="text"/> (Permissible range: 16 - 250) <input checked="" type="radio"/> kg <input type="radio"/> lb</p><p>Pulse: <input type="text"/> (Permissible range: 30 - 250)</p><p>Resp.rate: <input type="text"/> (Permissible range: 5 - 50)</p><p>00:00 <input type="button" value="Start examination"/> <input type="button" value="Cancel"/></p></div>



NID
(KOLIBRI with software KOLIBRI)

<p>Personal information</p> <hr/> <p>Full name</p> <input style="width: 90%;" type="text" value="Enter patient's full name"/> <p>Date of birth</p> <input style="width: 90%;" type="text" value="01/18/1966"/> <p>Gender</p> <p><input checked="" type="radio"/> Male <input type="radio"/> Female</p> <p>Contacts</p> <hr/> <p>Phone</p> <input style="width: 90%;" type="text" value="Enter patient's phone"/>	<p>Personal information</p> <hr/> <p>Full name</p> <input style="width: 90%;" type="text" value="Enter your full name"/> <p>Gender</p> <p><input checked="" type="radio"/> Male <input type="radio"/> Female</p> <p>Contacts</p> <hr/> <p>Phone</p> <input style="width: 90%;" type="text" value="Enter your phone"/> <p>Medical education</p> <hr/> <p>Specialization</p> <input style="width: 90%;" type="text" value="Enter your specialization"/> <p>Category</p> <input style="width: 90%;" type="text" value="Enter your category"/> <p>Science degree</p> <input style="width: 90%;" type="text" value="Enter your science degree"/>
---	---



KOLIBRI

Medical information

Weight Units
 kg lb

Height Units
 cm ft

Race
 ▼

Blood type
 ▼

Rh factor
 ▼

Bad habits

Smoking
 Yes No

Drugs
 Yes No

Diabetes

Patient doesn't have diabetes▼

Update diabetes status

ICD-10

Patient diseases

The patient has no diseases

Notes

B I U ≡ ≡ ≡ ≡ ≡ ≡ ↶ ↷

Test notes



KOLIBRI

19:48 14%

New staff

Enter staff name

Email Enter email

Gender female

Phone number Enter phone number

✓

12:09 83%

New patient

Anatolii

Date of birth 1966-01-18 EDIT

Gender male female

Weight 110 kg lb

Height 200 cm ft

Race Light-skin

Blood type Unknown

Rh factor Unknown

Diabetes Patient doesn't have di..

Phone number Enter phone number

Smoking

Using drugs

Notes

✓

14:56 61%

Ver 1908081742

Log into your KOLIBRI account

Email

Password

Show password

SIGN IN

Sign up Forgot password

18:30 52%

Staff patients permission

Staff name: Staff1
Email: 2020@mail.com
Phone number: 97379787
Your system balance is 262.6USD

	Free Patient 1, 34 years	<input type="checkbox"/>
	Free Patient 2, 121 years	<input type="checkbox"/>
	Patient 3 mobile, 35 years	<input type="checkbox"/>
	Patient 4, 64 years	<input type="checkbox"/>

✓



3. Storage Limitation

GDPR Article 5 (e): kept in a form which permits identification of data subjects for no longer than is necessary for the purposes for which the personal data are processed; personal data may be stored for longer periods insofar as the personal data will be processed solely for archiving purposes in the public interest, scientific or historical research purposes or statistical purposes in accordance with Article 89(1) subject to implementation of the appropriate technical and organizational measures required by this Regulation in order to safeguard the rights and freedoms of the data subject.

SCIENTIFIC COMPANY KOLIBRI LLC products support users to adhere to the GDPR principle of Storage Limitation. Our products enable a built-in function that can delete patient information stored in it when it is no longer necessary or after it is used. Our users can use this function to clear all sensitive personal data according to internal data retention policies or at the data subject's request. As the role of processor, SCIENTIFIC COMPANY KOLIBRI LLC products will help controllers (e.g. hospitals, doctors) to facilitate them better managing data in compliance with GDPR.

For example, SCIENTIFIC COMPANY KOLIBRI LLC NID products can record test results over some time.

The user can delete the research results manually.

The user can selectively delete personal data or research results manually. The user can delete all his results by deleting a personal electronic account.

4. Integrity and Confidentiality

GDPR Article 5 (f): processed in a manner that ensures appropriate security of the personal data, including protection against unauthorised or unlawful processing and accidental loss, destruction or damage, using appropriate technical or organisational measures.

SCIENTIFIC COMPANY KOLIBRI LLC always highly values the security of personal data. SCIENTIFIC COMPANY KOLIBRI LLC ensures that all personal data will be protected against unauthorised or unlawful processing and accidental loss, destruction or damage. In SCIENTIFIC COMPANY KOLIBRI LLC, we take a layered approach to security – using both technology and managerial methods.

When viewing and transmitting data (web software), we use https protocols.

For example, SCIENTIFIC COMPANY KOLIBRI LLC NID products have a Patient Data Management System to manage and protect patient data records. A patient data record consists of the following information:

- Patient basic information and exam data
- Image files
- Report

To better manage records, the Patient Data Management System supports users to save, edit, delete and transfer patient data. Also, NID products have Access Control, which sets up four different types of user accounts: Administrator, Operator, Operator-Doctor, Medical staff.

- Administrator

The system administrator does not have access to personal data. He can configure the system as a whole (determine tariff zones, set tariff plans, see general statistics that do not contain personal data). Conduct financial monitoring and others.



- Operator

The operator can view and delete research information stored in the system and managed by him independently. The operator can change and correct medical information about himself.

- Operator-Doctor

The operator-doctor can view and delete information about the study, stored in the system and managed by him independently. An operator-doctor can view research data that is managed by other medical staff.

The operator-doctor can change and correct the medical information about the patient.

- Medical staff

The medical staff can view and add information about the study, correct medical information (such as patient weight) stored in the system and managed by him independently.

A valid password is required to log in to identify your account type. This security control is designed to prevent misuse of the system.


Meanwhile, SCIENTIFIC COMPANY KOLIBRI LLC also allows users to change the password if the user considers it unreliable.

Table 6.


NID
(AMP, ANESA, DAD-ANI with software USPIH)

The screenshot displays the user interface for the NID system. At the top, there is an authentication window titled 'Authentication' with a close button (X). It contains two input fields: 'Login:' with the value '123456' and 'Password:'. Below these fields are two buttons: 'Save' and 'Enter'. Below the authentication window is a settings menu. The menu starts with 'Language ?' and a row of icons: a star, a clock, a paperclip, a printer, and a gear. The menu items are: 'Company details', 'Program update', 'Set defaults', 'Protection', and 'Selected parameters'. Under the 'Protection' section, there is a checkbox labeled 'Show the characters in the password' which is currently unchecked. To the right of this checkbox are two buttons: 'Enable password protection' and 'Change password'.

NID (KOLIBRI with software KOLIBRI)



14:56 61%


Ver 1908081742

Log into your KOLIBRI account


Email

Password

Show password

SIGN IN

[Sign up](#) [Forgot password](#)



Log into your KOLIBRI account

Email

Password

Sign in

[Don't have an account? Sign up](#) [Forgot password?](#)

Change email

Email

Current password

Change email

Change password

New password



5. Accountability

GDPR Article 5: the controller shall be responsible for, and be able to demonstrate compliance with, paragraph 1.

According to GDPR, SCIENTIFIC COMPANY KOLIBRI LLC implements not only internal and publicly-facing policies, records and notices, but also technical measures, and fundamental personnel and strategic changes to their processing operations. In the product research and development phase, SCIENTIFIC COMPANY KOLIBRI LLC performs Privacy by Design (PbD) work processes to enhance the comprehensive data protection mechanism. For example, SCIENTIFIC COMPANY KOLIBRI LLC products KOLIBRI provide log functioning to record system activities. The system activities, including failures, abnormalities and technical alarms, is stored in the log.

The USPIH software and StarDevice software is protected by an encryption key. This function can prevent unauthorised use of products. The system log records in detail all system activities of the products so that it is convenient for medical professionals to trace any improper operations.

GDPR Rights of the Data Subject.

The incoming GDPR will provide data subjects with enhanced rights over the use of personal data. Through these rights, data subjects can make a specific request and be assured that personal data is not being misused for purposes other than the legitimate purpose for which it was originally provided. SCIENTIFIC COMPANY KOLIBRI LLC always puts the user's needs in top priority while pursuing advanced technology. To help you better understand Company efforts, we explain it specifically as follows:

1. Right of access by the data subject.

GDPR Article 15: the data subjects shall have the right to obtain from the controller confirmation as to whether or not personal data concerning him or her is being processed, and, where that is the case, access to the personal data.

SCIENTIFIC COMPANY KOLIBRI LLC products can facilitate our users, namely the controllers, taking appropriate measures to provide information relating to the processing of personal data in a concise, transparent, intelligible and easily accessible form. SCIENTIFIC COMPANY KOLIBRI LLC products are able to generate a standard electronic report automatically, which demonstrates what data will be collected and how to process it. For example, SCIENTIFIC COMPANY KOLIBRI LLC NID products can generate a report for patients that consists of three parts. The first part is patient information used for identification purposes. The second part is testing parameters and results. The third part is relevant information used for clinical audit investigation. There is a sample report as follows :



Table 7.

NID (AMP, ANESA, DAD-ANI with software USPIH)					
<i>[Name/ contact info/ logo of the company-user]</i> <i>[Patient's Name/Surname/ID]</i> <i>[Date and Time of examination]</i>					
Gender: male Age: 48 Weight(kg): 86 Pulse: 81 Resp.rate: 18 Atm.pres: 752,71					
LCA: 35,14	RCA: 34,76	LAC: 36,36	RAC: 36,1	ABD: 33,89	176,25 99999
<p>Preliminary computer conclusion about possible pathologies: Asthenic-autonomic syndrome is determined. Protein S100 should be monitored. It is necessary to get a consultation of a gastroenterologist (Gastroduodenitis should be verified). Distinct reduction of leucocytes is determined. Hypochromic anemia is defined. It is recommended to get the consultation of hematologist, gastroenterologist, oncologist. Spinal osteochondrosis is defined. Disorders of water-electrolytic metabolism is determined. Ca of plasma is changed (Ca of bone tissue). Increasing of enzymes activity (aspartate transaminase, alanine transaminase) is determined. Hypertension of pulmonary circulation is defined. Width of the third ventricle of cerebrum =6,11. Derangement of oxidative phosphorylation is determined. Activation of lipid exchange is determined. Reduction of amino acid synthesis is defined (tyrosine, glutamine). Impact of ethanol should be verified. Dopamine β-hydroxylase (DBH) =21,8</p>					
<p><small>Disclaimer.</small> The above medical information is provided as a resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information is not intended to be patient education, does not create any patient – physician relationship, and shouldn't be used as a substitute for professional diagnosis and treatment. Any health decisions or guidance about specific medical condition are to be made only by Doctors or health care providers. In no circumstance, the device shall replace biochemical laboratory analysis. This device manufacturer expressly disclaims responsibility and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this report.</p>					
Signature of patient _____					
<p><small>GDPR: I have been briefed on my rights and Privacy Policy based on the REGULATION (EU) 2016/679 (GDPR) regarding the processing and movement of the personal data, which are used for the purposes of non-invasive hemogram screening, provided by the software USPIH. I am aware of and agree with the condition that the data containing in the database of the software USPIH will not be disclosed and/or forwarded to unauthorised third parties except the following: a) to a personal data processor (a professional, who is responsible for carrying out an examination on site); b) to the respective/authorised staff of the manufacturer, whose duties includes elimination of bugs in the software USPIH, software update or other assistance related to the software USPIH on the request of the personal data processor; c) to governments, control agencies, regulatory authorities and others as permitted or required by law. I am aware of an ability to withdraw my consent at any time submitting a written statement in the place, where the service was provided. Thereof, I realise that my personal data will be deleted irrevocably and without a possibility of further applying, referring and analysing of such a data.</small></p>					
Signature of patient _____					
<p>The following parameters were simultaneously captured to issue the above preliminary report.</p>					
No.:		Parameter:	Norm:	<	>
1	2	Erythrocytes RBC. x10 ¹² /l	4 - 5,6		4,61
2	1	Hemoglobin HGB. mg/dl	12,5 - 17,5		15,11
3	88	Hematocrit. HCT 0.01*%	0,35 - 0,49		0,42
4	12	Thrombocytes. x10 ⁹ /l	1,8 - 3,2		1,97
5	4	Leukocytes WBC. x10 ⁹ /l	4,3 - 11,3	3,71	



KOLIBRI

6	3	Lymphocytes. LYMPH %	19 - 37			38,39
7	8	Monocytes. MONO %	3 - 11		7,52	
8	42	Glucose. mg/dl	71,9 - 107,9		89,85	
9	35	Cholesterol total. mg/dl	120 - 250,19		224,88	
10	38	Low-density lipoproteins (LDL). mg/dl	104,25 - 130,12			131,69
11	40	High-density lipoproteins (HDL). mg/dl	30 - 67		32,98	
12	41	Triglycerides (TG). mg/dl	48,67 - 163,72			192,32
13	25	ALT. (SGPT). U/l	5 - 30			115,47
14	24	AST. (SGOT). U/l	8 - 40			114,45
15	27	Bilirubin, Total. mg/dl	0,5 - 1,198		1,07	
16	31	Creatinine. mg/dl	0,62 - 1,39	0,60		
17	34	Urea. mg/dl	12,8 - 49,2		28,22	
Hemogram:						
18	1	Hemoglobin HGB. mg/dl	12,5 - 17,5		15,11	
19	2	Erythrocytes RBC. x10 ¹² /l	4 - 5,6		4,61	
20	4	Leukocytes WBC. x10 ⁹ /l	4,3 - 11,3	3,71		
21	120	Mean cell haemoglobin (MCH). pg	26 - 32			33
22	121	Mean cell volume (MCV). fl	81 - 94		91	
23	122	Mean cell haemoglobin concentration (MCHC). g/l	310 - 350			362
24	123	CPB (Color index of blood).	0,85 - 1,15		0,98	
25	3	Lymphocytes. LYMPH %	19 - 37			38,39
26	5	Segmented neutrophils. NEUT %	47 - 72		47,73	
27	7	Eosinophils. %	0,5 - 5,8		2,15	
28	8	Monocytes. MONO %	3 - 11		7,52	
29	9	Band neutrophils. NEUT %	1 - 6		4,21	
30	6	Erythrocyte sedimentation rate ESR. mm/h	1 - 14		11,41	
Blood coagulation:						
31	10	Beginning of clotting (method of Lee-White). min	0,5 - 2			02'04''
32	11	End of clotting (method of Lee-White). min	3 - 5		03'29''	
33	12	Thrombocytes. x10 ⁹ /l	1,8 - 3,2		1,97	
34	86	Fibrinogen. mg/dl	200 - 400		358,98	
35	87	Prothrombin index (PI). %	75 - 104		76,19	
36	88	Hematocrit. HCT 0.01*%	0,35 - 0,49		0,42	
Electrolyte metabolism:						
37	13	Calcium (Ca). mg/dl	9 - 12	8,63		
38	14	Magnesium (Mg). mg/dl	1,6 - 2,6		2,32	
39	15	Potassium (K). mg/dl	13,59 - 20,7		15,01	
40	16	Sodium (Na). mmol/l	136 - 145		141,28	
41	128	Chloride (Cl). mg/dl	347,41 - 379,315		356,4	
Functional parameters of stomach:						
42	17	pH of gastric juice.	1,2 - 1,7		1,22	
43	19	SH.	7,32 - 7,4			8,51
44	20	Basal pressure of Oddi's sphincter mm Hg	39 - 41			42,87



KOLIBRI

		Carbohydrate metabolism:			
45	33	Lactic acid. mg/dl	9 - 12,55		14,64
46	42	Glucose. mg/dl	71,9 - 107,9		89,85
47	43	Glycogen. mg%	11,7 - 20,6		15,17
		Liver function tests:			
48	22	Aspartate transaminase (AST). mmol/l	0,1 - 0,45		2,36
49	23	Alanine transaminase (ALT). mmol/l	0,1 - 0,68		2,38
50	24	AST. (SGOT). U/l	8 - 40		114,45
51	25	ALT. (SGPT). U/l	5 - 30		115,47
52	26	De Ritis coefficient (AST/ALT).	0,8 - 1,2		0,99
53	27	Bilirubin, Total. mg/dl	0,5 - 1,198		1,07
54	28	Bilirubin, Direct. mg/dl	0,129 - 0,357		0,28
55	29	Bilirubin, Indirect. mg/dl	0,371 - 0,841		0,79
		Protein metabolism:			
56	30	Protein, Total. g/dl	6 - 8,5		6,76
57	133	Serum albumin (ALB). g/dl	3,4 - 4,5		3,9
58	134	Serum globulin (GLB). g/dl	2 - 4,5		2,4
59	31	Creatinine. mg/dl	0,62 - 1,39	0,60	
60	32	Dopamine β-hydroxylase (DBH). nm/ml/min	28 - 32,5	21,79	
61	34	Urea. mg/dl	12,8 - 49,2		28,22
		Lipid metabolism:			
62	41	Triglycerides (TG). mg/dl	48,67 - 163,72		192,32
63	38	Low-density lipoproteins (LDL). mg/dl	104,25 - 130,12		131,69
64	39	Very low-density lipoproteins (VLDL). mg/dl	7,72 - 20,07		14,52
65	40	High-density lipoproteins (HDL). mg/dl	30 - 67		32,98
66	35	Cholesterol total. mg/dl	120 - 250,19		224,88
67	36	β- lipoprotein. g/l	17 - 55		44,46
68	37	β- lipoprotein. mmol/l	3 - 6		4,53
69	132	Atherogenic factor (KA).	0,71 - 5,36		5,82
		Water metabolism:			
70	45	Cellular water. %	39 - 42		41,19
71	46	Total water. %	50 - 70		54,23
72	44	Extracellular water. %	21 - 23		22,49
		Hormones:			
73	47	Testosterone. μmol/24hours	6,93 - 17,34		20,10
74	48	Estrogen, Total . nmol/24hours	17,95 - 64,62	11,99	
75	49	Thyroxine (T4),Total. μg/dl	4,6 - 10,5		5,5
		Enzymes:			
76	50	Amylase (W.T.Caraway). g/l*h	12 - 32		29,34
77	51	Acetylcholine. μg/ml	81,1 - 92,1		82,76
78	52	Acetylcholinesterase of erythrocytes. μmol/l	220 - 278		268,24
79	54	Tyrosine. μmol/l	77,3 - 82,8	76,33	
80	55	Creatine kinase MM (CK-MM). μmol/min/kg	473 - 483		474,31



KOLIBRI

81	56	Creatine kinase MB (CK-MB). µmol/min/kg	35,1 - 38,1		35,78	
Cell mitosis regulation:						
82	57	Comprehensive cell mitosis regulation factor.	3,7828 - 3,9372			4,3302
Internal blood flow, in % to total blood flow:						
83	64	Myocardial blood flow. %	4,32 - 5,02		4,35	
84	65	Muscular blood flow. %	14,56 - 16,93		16,82	
85	66	Cerebral blood flow. %	12,82 - 14,9		14,24	
86	67	Hepatoportal blood flow. %	20,28 - 29,86		24,81	
87	68	Nephritic blood flow. %	21,58 - 25,09			27,24
88	69	Skin blood flow. %	7,9 - 9,19		8,09	
89	70	Blood flow of other organs. %	5,76 - 6,7			6,74
Internal blood flow, in ml/min:						
90	71	Myocardial blood flow. ml/min	250 - 290,5		251,73	
91	72	Muscular blood flow. ml/min	930 - 1081,4		1 074,60	
92	73	Cerebral blood flow. ml/min	750 - 871,68		832,91	
93	74	Hepatoportal blood flow. ml/min	1690 - 2488,33		2 067,85	
94	75	Nephritic blood flow. ml/min	1430 - 1662,6			1 804,99
95	76	Skin blood flow. ml/min	500 - 581,65		511,73	
96	77	Blood flow of other organs. ml/min	375 - 436,19			438,78
Cerebral hemodynamics:						
97	82	Cerebral blood flow on 100g of tissue. ml/100g	50 - 55		52,98	
98	83	Blood flow per 1gr of thyroid gland. ml/g	3,7 - 4,3		3,90	
99	84	Blood flow per 1gr of cerebral tissue. ml/g	2,9 - 3,2		3,10	
100	85	Cerebral spinal fluid pressure (CSF). mm H ₂ O	90 - 145		125,62	
101	116	Width of the third ventricle of cerebrum. mm	4 - 6			6,11
Functional parameters of cardio-respiratory system:						
102	78	Pulmonary vascular resistance (PVR). dyn/cm ⁵ *sec	160 - 250	148,05		
103	79	Central venous pressure. mm H ₂ O	70 - 150	67,51		
104	80	Time of pulmonary circulation. s	16 - 23			24,39
105	81	Time of systemic circulation. s	4 - 5,5			5,70
106	21	Energy Expenditure. kkal/kg/min	1,23 - 4,3			6,04
107	61	Oxygenation velocity of RBC. ml/min	260 - 280	224,35		
108	62	Surface of gaseous exchange of RBC. m ²	3500 - 4300		3 677,92	
109	63	Deficit of circulatory blood. ml/kg	0 - 250		75,80	
110	89	Vital capacity of lungs (VC). cm ³	3500 - 4300		3 567,06	
111	90	Minute ventilation (VE) l/min	4 - 12			12,68
112	91	Functional residual capacity (FRC) cm ³	-----		1 855,50	
113	92	Peak expiratory flow (PEF). l/min	74 - 116		82,90	
114	93	Test Tiffeneau. %	84 - 110	79,16		
115	94	Working rate of oxygen consumption. %	45 - 60			74,62
116	95	Time of single load. min	3 - 10		9,54	
117	96	Respiratory exchange ratio (RER).	0,8 - 1,2		0,87	
Oxygen transport and consumption:						



KOLIBRI

118	18	pH of blood.	7,36 - 7,45	7,24		
119	59	Volume of circulatory blood. ml/kg	68 - 70			80,54
120	60	Cardiac output (CO). l/min	3,5 - 4,3			5,46
121	97	Transportation of oxygen(O ₂). ml/min	900 - 1200		1 126,09	
122	98	Quantity of assimilated oxygen on 100 gr. of cerebral tissue. ml	2,8 - 3,4	2,28		
123	99	Oxygen saturation in arterial blood (SaO ₂). %	95 - 98	92,98		
124	100	Oxygen consumption per kg of body weight. ml/min/kg	4 - 6		4,86	
125	101	O ₂ consumption. (VO ₂) ml/min	200 - 250			276,12
126	102	Myocardial oxygen consumption. ml/min	7 - 10		9,62	
127	103	Oxygen extraction index. %	26 - 34		31,3	
Transport and elimination of CO₂:						
128	104	CO ₂ elimination. ml/min	119 - 300		283,07	
129	105	(CO ₂) in arterial blood. %	32,5 - 46,6			47,72
130	106	(CO ₂) venous blood. %	51 - 53			53,33
131	107	Rate of CO ₂ production. ml/min	150 - 340			350,06
Functional parameters of cardio-vascular system:						
132	108	Vascular Permeability Index.	4,165 - 4,335	4,030		
133	109	Stroke volume (SV). ml	60 - 80		70,95	
134	110	Interval PR. sec	0,125 - 0,165		0,149	
135	111	Interval QT. sec	0,355 - 0,4			0,411
136	112	Interval QRS. sec	0,065 - 0,1			0,110
137	113	Left ventricular Stroke Work Index. %	52 - 60			66,05
138	114	Systolic arterial pressure. mm Hg	-----		124,03	
139	115	Diastolic arterial pressure. mm Hg	-----		89,45	
140	58	Plasma density. g/l	1048 - 1055		1 050,06	
141	117	Cardiac work. Joule	0,692 - 0,788	0,63		
----- Out of group						
142	118	eGFR [MDRD]. ml/min/1.73m ²	95 - 145			153,6
143	119	Estimated creatinine clearance rate(eCCr)[Cockroft and Gault]. ml/min	95 - 145			184,0
144	124	Cystatin C (CysC). mg/l	0,6 - 0,96	0,58		
145	125	BUN. mg/dl	6 - 23		13	
146	126	Transferrin. mg/dl	204 - 380		239,75	
147	127	Urine specific gravity. g/cm ³	1005 - 1035		1 019	
148	129	Ceruloplasmin (CP). mg/l	150 - 600		469,516	
149	130	Alkaline phosphatase (ALP). U/L	38 - 119		96,13	
150	131	Intracranial pressure (ICP). mmHg	7 - 15		9,2	

Table 8.

NID
(KOLIBRI with software KOLIBRI)



PERSONAL SCREENING SYSTEM



Doctor

Full name: **CZ CLINIC**
Specialization: **None**
Category: **PHD**
Science degree: **Free**
Phone: **+971557702115**

Clinic

Name: **«International Technology Center FZC»**
Address: **P.O.Box 330102, Ras Al Khaimah, United Arab**
Phone: **+971557702115**

Patient 4

Date of birth: **05/11/1955 (64 years)**
Sex: **Female**
Weight: **100 kg**
Height: **170 cm**
Blood type: **—**

Test No. 24

09/19/2019, 08:33 AM
Executor: **www Staff 2**
Signal quality: **98 High**
Noise level: **10 Low**

General parameters

Parameter	Result	Units	Normal Ranges	RL index
Heart rate	72	bpm	60 — 90	100%
Health index	1	-	0 — 2	98%
Stress index	160	-	60 — 220	98%
Body mass index	34	kg/m^2	18 — 25	100%
Basal metabolic rate	1581	kcal	0 — 1400	100%
Energy Expenditure	4	kcal	0 — 1400	98%

CBC and blood pressure

Parameter	Result	Units	Normal Ranges	RL index
Systolic blood pressure	117	mmHg	120 — 130	80%
Diastolic blood pressure	79	mmHg	70 — 80	80%

ATTENTION! KOLIBRI is the screening system. Interpretation of the results and diagnosing must be made by a physician/professional only. Results of the test are not considered as a decisive for making a diagnosis.

Test No. 24 | 09/19/2019, 08:33 AM | www.kolibri.one

1/5



Parameter	Result	Units	Normal Ranges	RL index
Hemoglobin (HGB)	139	g/l	120 — 160	80%
Hematocrit	38	-	37 — 47	80%
Platelets	282	10 ⁹ /L	150 — 450	80%
Red blood cells	3.9	10¹²/L	4.2 — 5.4	80%
White blood cells	4.5	10 ⁹ /L	4 — 11	80%

Heart rate variability (HRV)

Parameter	Result	Units	Normal Ranges	RL index
Standard deviation of the normal-to-normal intervals	34	ms	32 — 93	98%
Index of adequacy of the regulatory processes	70	-	-	98%
Autonomic rate index	5	-	-	98%
Autonomic balance index	264	-	-	98%
Normalized index of summary effect of regulation	4.1	-	-	98%
Conditional index of activity of the sympathetic element of regulation	57	-	-	98%
The most probable level of functioning of cardiovascular system	0.82	-	-	98%
Maximum amplitude of regulatory influences	0.21	-	-	98%
Triangular interpolation of the normal-to-normal interval of a histogram	140	-	-	98%
HRV triangular index	9	-	-	98%
Deviation of heart rate	3.12	-	-	98%
Activity of parasympathetic autonomic regulation	14	ms	19 — 75	98%

ATTENTION! KOLIBRI is the screening system. Interpretation of the results and diagnosing must be made by a physician/professional only. Results of the test are not considered as a decisive for making a diagnosis.



Parameter	Result	Units	Normal Ranges	RL index
The number of cardiac intervals with a difference of more than 50 ms, %	0	-	-	98%
Mean RR-interval	73	bpm	52 — 76	98%
Min RR-interval	65	-	-	98%
Max RR-interval	85	-	-	98%
Poincare plot, SD1	10	-	-	98%
Poincare plot, SD2	47	-	-	98%
Detrended fluctuation analysis, alpha1	1.43	-	-	98%
Detrended fluctuation analysis, alpha2	1.09	-	-	98%
Normalized LF	83	%	30 — 65	98%
Normalized HF	16	%	16 — 60	98%
LF/HF Ratio	5.15	-	1.1 — 11.6	98%
Power in very low frequency range	759	-	-	98%
Power in low frequency range	308	ms ²	193 — 1009	98%
Power in high frequency range	59	ms²	83 — 3630	98%
Power in whole frequency range	1127	-	-	98%

Lipid metabolism

Parameter	Result	Units	Normal Ranges	RL index
Triglycerides (TG)	1.1	mmol/l	0.65 — 3.29	80%
Low-density lipoproteins (LDL-C)	3.5	mmol/l	2.59 — 5.8	80%
High-density lipoproteins (HDL-C)	1.7	mmol/l	0.98 — 2.38	80%
Cholesterol (CHOL)	5.7	mmol/l	4.45 — 7.69	80%

ATTENTION! KOLIBRI is the screening system. Interpretation of the results and diagnosing must be made by a physician/professional only. Results of the test are not considered as a decisive for making a diagnosis.



Carbohydrate metabolism

Parameter	Result	Units	Normal Ranges	RL index
Blood carbohydrate index	132	-	55.2 — 76.8	80%

Heart activity

Parameter	Result	Units	Normal Ranges	RL index
RR interval	824	ms	600 — 1200	98%
P-wave	104	ms	70 — 90	98%
PR segment	92	ms	50 — 120	98%
PR interval	196	ms	120 — 200	98%
QRS complex	88	ms	65 — 100	98%
QT interval	368	ms	355 — 440	98%
ST segment	76	ms	80 — 120	98%
ST interval	284	ms	270 — 320	98%
T-wave	208	ms	130 — 160	98%
Morphology of T-wave	Normal	-	Normal	98%
QTc interval	405	ms	350 — 460	98%

Electrolytic metabolism

Parameter	Result	Units	Normal Ranges	RL index
Potassium (K)	4.2	mmol/l	3.4 — 4.4	80%
Sodium (Na)	140	mmol/l	136 — 145	80%
Calcium (Ca)	2.2	mmol/l	2.25 — 3	80%

ATTENTION! KOLIBRI is the screening system. Interpretation of the results and diagnosing must be made by a physician/professional only. Results of the test are not considered as a decisive for making a diagnosis.



PERSONAL SCREENING SYSTEM



ECG

Heart rate: 72 bpm

20 mm/mV 50 mm/s



ATTENTION! KOLIBRI is the screening system. Interpretation of the results and diagnosing must be made by a physician/professional only. Results of the test are not considered as a decisive for making a diagnosis.

Test No. 24 | 09/19/2019, 08:33 AM | www.kolibri.one

5/5



2. Right to rectification

GDPR Article 16: the data subject shall have the right to obtain from the controller without undue delay the rectification of inaccurate personal data concerning him or her.

Taking into account the purposes of the processing, the data subject shall have the right to have incomplete personal data completed, including by means of providing a supplementary statement.

According to the GDPR, data subjects have the right to immediately obtain from the dispatcher the correction of inaccurate personal data concerning him or her. Thus, SCIENTIFIC COMPANY KOLIBRI LLC developed the corresponding function of the system so that the controller can respond promptly to the requests of the data subject and, accordingly, make corrections.

SCIENTIFIC COMPANY KOLIBRI LLC has developed a Personal Account in the cloud, which is a patient data management system (KOLIBRI) and the USPIH program.

It is easy for users to manage and correct patient data, including necessary patient information, examination information, image files and reports. See table 5.

3. Right to Erase (The right to be forgotten)

GDPR Article 17: the data subject has the right to receive from the controller the deletion of personal data relating to him without undue delay, and the controller is obliged to erase personal data without undue delay ...

To help the controller comply with the right of deletion, SCIENTIFIC COMPANY KOLIBRI LLC products provide functions to delete personal data accordingly. For example, NID products can help our users delete data that is no longer needed for its original purpose, or the user has withdrawn his consent.

a) For USPIH cloud software:

The use of personal data is completely excluded. The USPIH software uses for processing on a cloud mathematical server: temperature values, gender, patient weight, patient age, pulse, atmospheric pressure and respiratory rate. This data does not apply to personal data.

b) For local USPIH software:

For local USPIH software, a mechanism for deleting personal data stored in a local database is implemented. To do this, use the menu "Delete patient" or "Delete examination."

c) For the software of the Personal screening non-invasive diagnostic system of KOLIBRI:

For cloud and local software, a mechanism has been implemented to delete personal data stored in the user's account (last name, first name, date of birth, e-mail) at the request of the client. To delete personal data together with your personal electronic account, you must follow the deletion procedure (pressing a button) and confirm the deletion of personal data and your personal electronic account in your e-mail. You must remember that such data as weight, height, gender, race, age and electronic signals sent by you to the cloud mathematical server for processing will remain in our database, but they will be impersonal and not related to personal data. After the destruction of your (personal) data and personal account, the restoration of the results of your non-invasive diagnostics becomes impossible.



KOLIBRI

4. Right to data portability

GDPR Article 17: the data subject shall have the right to receive the personal data concerning him or her, which he or she has provided to a controller, in a structured, commonly used and machine-readable format and has the right to transmit that data to another controller without hindrance from the controller to which the personal data has been provided...

a) For software USPIH:

The USPIH software allows you to export data from the results of a patient examination to a paper medium and files of the HTML or PDF format. This enables you to realize the right to data portability.

b) For the KOLIBRI software:

The KOLIBRI software allows you to export data from the results of a patient examination onto paper and PDF files with the subsequent transfer of files via email. This enables you to realize the right to data portability.

The KOLIBRI software allows you to remotely connect the transfer of the results of your research to the doctor's cloud account and the function of displaying the test results in the doctor's account in real-time is implemented.

This allows you to realize the right to data portability.

